An update on current and prospective immunotherapies for chronic lymphocytic leukemia.
Chronic lymphocytic leukemia (CLL) is the most common leukemia. Combined agent chemotherapy is the current standard front-line treatment for physically fit patients with CLL. Use of chemotherapy can be complicated by significant toxicity, especially in patients with advanced age or comorbid conditions. Moreover, patients may relapse and become refractory to further chemotherapy. Immunotherapy targets the aberrant immunological processes in CLL without the toxicity of chemotherapy. Immunotherapeutic strategies can also be combined with chemotherapy to improve response rates in this incurable disease. In this review, we evaluate current and future immune-based options in the treatment of CLL.
Department of Malignant Hematology, H Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA.
Josephine N
JN
Emole
Frederick L
FL
Locke
Javier
J
Pinilla-Ibarz
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000628:therapy*; D008213:Lymphocyte Activation; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
bispecific T-cell engager; chimeric antigen receptor; chronic lymphocytic leukemia; immunotherapy; monoclonal antibody